anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thirty subjects who are scheduled to receive an Empowr PS Total Knee Replacement device will be consented to be in the prospective component of the study. Twenty of these patients will participate in motion data collection. These patients will all be scheduled to undergo primary total knee replacement using the Empowr device. All surgeries will be performed using computer navigation. Patients will receive standardized physical therapy to insure consistency of rehab protocols and discharge from physical therapy criteria. Specifically, patients will be monitored for visit compliance, Timed Up and Go (TUG) test in seconds, AROM in degrees, and walking un-aided.

Data were previously collected preoperatively, at 6 months and 1 year post-operatively for 16 patients who received a Stryker Triathlon total knee replacement and preoperatively and 1 year post-op for 16 patients who received a Biomet Vanguard total knee replacement. Data were also previously collected for 20 age matched healthy controls subjects. Data will be collected for an additional 20 control subjects. Knee Society Score (KSS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) will be collected at pre-op, 6 months, 1 year, and 2 years post-op. Gait analysis data will include kinetic, kinematic, temporal spatial, and electromyographic (EMG) data throughout the gait cycle for both research subjects and controls. Reflective markers will be placed on subject's anatomical landmarks, and ten surface EMG electrodes placed according to published standards (8). Subjects will walk at a self-selected speed down a runway embedded with force plates while 10 Eagle-4 digital infrared cameras record their movement. In addition to the level surface walking, additional data on more complex activities of daily living will be collected for potential future analysis. This would include: sit-to-stand, balance, and stair-climbing measurements also using the force plates, camera system and EMG data collection.
BACKGROUND AND PURPOSE: Ischaemia-reperfusion (I/R) injury is a major contributor to skin flap necrosis, which presents a challenge in achieving satisfactory therapeutic outcomes. Previous studies showed that cathelicidin-BF (BF-30) protects tissues from I/R injury. In this investigation, BF-30 was synthesized and its role and mechanism in promoting survival of I/R-injured skin flaps explored.
EXPERIMENTAL APPROACH: Survival rate analysis and laser Doppler blood flow analysis were used to evaluate I/R-injured flap viability. Western blotting, immunofluorescence, TdT-mediated dUTP nick end labelling (TUNEL) and dihydroethidium were utilized to examine the levels of apoptosis, pyroptosis, oxidative stress, transcription factor EB (TFEB)-mediated autophagy and molecules related to the adenosine 5'-monophosphate-activated protein kinase (AMPK)-transient receptor potential mucolipin 1 (TRPML1)-calcineurin signalling pathway.
KEY RESULTS: The outcomes revealed that BF-30 enhanced I/R-injured island skin flap viability. Autophagy, oxidative stress, pyroptosis and apoptosis were related to the BF-30 capability to enhance I/R-injured flap survival. Improved autophagy flux and tolerance to oxidative stress promoted the inhibition of apoptosis and pyroptosis in vascular endothelial cells. Activation of TFEB increased autophagy and inhibited endothelial cell oxidative stress in I/R-injured flaps. A reduction in TFEB level led to a loss of the protective effect of BF-30, by reducing autophagy flux and increasing the accumulation of reactive oxygen species (ROS) in endothelial cells. Additionally, BF-30 modulated TFEB activity via the AMPK-TRPML1-calcineurin signalling pathway.
CONCLUSION AND IMPLICATIONS: BF-30 promotes I/R-injured skin flap survival by TFEB-mediated up-regulation of autophagy and inhibition of oxidative stress, which may have possible clinical applications.
BACKGROUND/AIM: Alterations in gut microbiota are associated with the pathogenesis of metabolic diseases, including metabolic-associated fatty liver disease (MAFLD). The aim of this study was to evaluate gut microbiota composition and functionality in patients with morbid obesity with different degrees of MAFLD, as assessed by biopsy.
SUBJECTS/METHODS: 110 patients with morbid obesity were evaluated by biopsy obtained during bariatric surgery for MAFLD. Stool samples were collected prior to surgery for microbiota analysis.
RESULTS: Gut microbiota from patients with steatosis and non-alcoholic steatohepatitis (NASH) were characterized by an enrichment in Enterobacteriaceae (an ethanol-producing bacteria), Acidaminococcus and Megasphaera and the depletion of Eggerthellaceae and Ruminococcaceae (SCFA-producing bacteria). MAFLD was also associated with enrichment of pathways related to proteinogenic amino acid degradation, succinate production, menaquinol-7 (K2-vitamin) biosynthesis, and saccharolytic and proteolytic fermentation. Basic histological hepatic alterations (steatosis, necroinflammatory activity, or fibrosis) were associated with specific changes in microbiota patterns. Overall, the core microbiome related to basic histological alterations in MAFLD showed an increase in Enterobacteriaceae and a decrease in Ruminococcaceae. Specifically, Escherichia coli was associated with steatosis and necroinflammatory activity, whilst Escherichia-shigella was associated with fibrosis and necroinflammatory activity.
CONCLUSIONS: We established a link between gut microbiota alterations and histological injury in liver diagnosis using biopsy. Harmful products such as ethanol or succinate may be involved in the pathogenesis and progression of MAFLD. Thus, these alterations in gut microbiota patterns and their possible metabolic pathways could add information to the classical predictors of MAFLD severity and suggest novel metabolic targets.
PCT No. PCT/JP96/01438 Sec. 371 Date Oct. 10, 1997 Sec. 102(e) Date Oct. 10, 1997 PCT Filed May 29, 1996 PCT Pub. No. WO96/38173 PCT Pub. Date Dec. 5, 1996The present invention relates to a composition for treating or preventing brain edemas which comprises containing an endothelin antagonist as an active ingredient, for example, the compound of the following formula (I): or pharmaceutically acceptable salts or hydrates thereof, bosentan, cyclo[D-aspartyl-L-[3-(4-phenylpiperazin-1-ylcarbonyl)]-alanyl-L-aspartyl-D-[2-(2-thienyl)]glycyl-L-leucyl-D-tryptophyl]disodium or cyclo [D-Asp-L-Pro-D-Val-L-Leu-D-Trp]. Furthermore, the present invention provides a method for treating or preventing brain edemas, which comprises administering an effective amount of an endothelin antagonist and use of an endothelin antagonist for the manufacture of a medicament for treating or preventing brain edemas. An endothelin antagonist exhibits an inhibitory effect, on all brain edemas regardless of the onset mechanism and thus is highly useful in the treatment or prevention of brain edemas.A brain edema inhibitor which comprises as the active ingredient an endothelin antagonist, for example, a compound represented by general formula (I), pharmaceutically acceptable salts or hydrates thereof, bosentan, cyclo[D-aspartyl-L-[3-(4-phenylpiperazin-1-ylcarbonyl)]-alanyl-L-aspartyl-D-[2-(2-thienyl)]glycyl-L-leucyl-D-tryptophyl] disodium or cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp]. A method for treating or preventing brain edemas by administering an endothelin antagonist in an effective dose and use of an endothelin antagonist in the production of a medicine for treating or preventing brain edemas. An endothelin antagonist exhibits an inhibitory effect on all brain edemas regardless of the onset mechanism and thus is highly efficacious in the treatment or prevention of brain edemas.
Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH) 2  (a strong adsorbent for arsenic) doped with a divalent or trivalent metal cation is used to adsorb arsenic. The complex consisting of arsenic adsorbed on Mg(OH) 2  doped with a divalent or trivalent metal cation is subsequently removed from the water by conventional means, including filtration, settling, skimming, vortexing, centrifugation, magnetic separation, or other well-known separation systems. In another embodiment, magnesium oxide, MgO, is employed, which reacts with water to form Mg(OH) 2 . The resulting Mg(OH) 2  doped with a divalent or trivalent metal cation, then adsorbs arsenic, as set forth above. The method can also be used to treat human or animal poisoning with arsenic.
BACKGROUND: Rabies PEP consists of thorough wound cleansing, administration of HRIG 20 IU/kg body weight, and 4 to 5 doses of rabies vaccine. The safety of HRIG 300 IU/mL has been confirmed only for adult patients. Although the safety of HRIG 300 IU/mL in the pediatric population has not been fully established, there is no age limit on the FDA approved indication for HRIG 300 IU/mL, and it is routinely administered to pediatric patients as standard of care in the United States.

STUDY DESIGN: This observational, multicenter, prospective study will collect information on safety events that occur up to 30 days after standard of care administration of HRIG 300 IU/mL among pediatric patients (age ≤17 years) at up to 5 study sites in the United States. Safety data will be collected using surveys and chart review of the health record. All participants will receive HRIG 300 IU/mL per standard of care prior to joining this study. The day of HRIG 300 IU/mL administration will be defined as day 0. The study will conduct Survey 1 on day 2 and Survey 2 on day 10 to collect information on adverse events (AEs). Investigators will review the electronic health record on day 30 to collect additional information on AEs. If a serious adverse event is detected during Survey 1, Survey 2, or the 30-day chart review and is not previously documented as being resolved or stabilized the study will conduct Survey 3 on day 30.
Five recent clinical trials evaluated the effects of warfarin in patients with non-valvular atrial fibrillation (AF). Meta-analysis findings of these studies revealed that the effects of warfarin in reducing thromboembolic events including stroke were similar at either moderately high INR (2.0-4.5) or low INR (1.4-3.0). There was a significant reduction in minor bleeds at the low INR. There are no adequate and well-controlled studies in populations with atrial fibrillation and valvular heart disease. Similar data from clinical studies in valvular atrial fibrillation patients are not available. The trials in non-valvular atrial fibrillation support the American College of Chest Physicians’ (7th ACCP) recommendation that an INR of 2.0-3.0 be used for warfarin therapy in appropriate AF patients.17

Oral anticoagulation therapy with warfarin is recommended in patients with persistent or paroxysmal AF (PAF) (intermittent AF) at high risk of stroke (i.e., having any of the following features: prior ischemic stroke, transient ischemic attack, or systemic embolism, age >75 years, moderately or severely impaired left ventricular systolic function and/or congestive heart failure, history of hypertension, or diabetes mellitus). In patients with persistent AF or PAF, age 65 to 75 years, in the absence of other risk factors, but who are at intermediate risk of stroke, antithrombotic therapy with either oral warfarin or aspirin, 325 mg/day, is recommended. For patients with AF and mitral stenosis, anticoagulation with oral warfarin is recommended (7th ACCP). For patients with AF and prosthetic heart valves, anticoagulation with oral warfarin should be used; the target INR may be increased and aspirin added depending on valve type and position, and on patient factors.17
Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
Laparoscopic subtotal cholecystectomy (LSC) is utilized to prevent complications in the difficult cholecystectomy. Medium-term outcomes are poorly studied for fenestrating and reconstituting operative techniques. A single-institution retrospective review was undertaken of all LSCs. A telephone survey was used to identify complications addressed at other institutions. We performed subgroup analyses by operative approach and of patients requiring postoperative endoscopic intervention (ERC). 28 patients met inclusion criteria. The median follow-up was 32.7 months. There were no bile duct injuries or reoperations. 21% of patients required a postoperative ERC and 50% were discharged home with a drain. Bile leaks were found to be more prevalent in the fenestrating LSC group (38% vs 0%, P = .003). The case series suggested more severe recurrent biliary disease in patients undergoing reconstituting LSC. Laparoscopic subtotal cholecystectomy appears to have satisfactory medium-term outcomes. The reconstituting LSC group trends toward more severe recurrent disease which warrants further investigation.
Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
PURPOSE:To produce a spherical-shaped clay mineral, which is a bulking agent giving a excellent moldability to rubber or plastics and a compounding agent giving an excellent touch for use to a cosmetics by spray-drying an aqueous solvent dispersion of a clay mineral having a water swelling property. CONSTITUTION:The clay mineral having a water swelling property (e.g., a silicate mineral belonging to a smectite group such as a natural or synthetic monmorillonite, a saponite and a hectrorite, etc., is dispersed into an aqueous solvent and is gelled. On this occasion the dispersion liq. is preferable to contain the <=20wt% clay mineral having the water swelling property, more preferably 1-10wt%. Then the spherical shaped clay mineral is produced by spray-drying the dispersion liquid. Since the obtained clay mineral has a spherical shape, it is the excellent bulking agent giving a high moldability to plastics and rubber, etc., and the cosmetics having an excellent smoothy touch for use without variance is obtained by compounding it to the cosmetics as a dispersing and stabilizing agent.
Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID.
Cyclic peptides capable of inhibiting Gonadotropin Regulated Testicular Helicase (GRTH) phosphorylation are provided. The cyclic peptides showed effective delivery into COS-1 and germ cells and a dose-dependent inhibitory effect on GRTH phosphorylation. The cyclic peptides inhibit GRTH phosphorylation in the presence of PKA, and binding to the helicase resulted in thermal stabilization of non-phospho-GRTH. Increased efficiency in FRET assay revealed their interaction with GRTH. Cyclic peptide exposure of cultures from mice seminiferous tubules resulted in significant inhibition of phospho-GRTH. These cyclic peptides did not exhibit toxicity.
From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
PURPOSE: A complex antibacterial composition is provided to ensure excellent antibacterial activity against gram-positive bacteria and gram-negative bacteria, and to treat various infections. CONSTITUTION: A complex antibacterial composition contains 10-35wt% of enrofloxacin, 5-25wt% of trimethoprim, and 40-80wt% of sulfamethoxazole. The complex antibacterial composition contains enrofloxacin, trimethoprim, and sulfamethoxazole mixed in a weight ratio of 2:1:5. A drug for treating infectious diseases in an animal digestive system or an animal respiratory system contains the complex antibacterial composition as an active ingredient. The drug is manufactured in the form of powder, a pellet, a granule, an injection, or an ointment. [Reference numerals] (AA) Observation result after injecting the antibacterial composition of an example(%, mucous diarrhea)
The invention discloses a compound oral preparation and a preparation method thereof. The compound oral preparation is used for treatment of high blood pressure and has significant effect. The preparation includes three anti-hypertensive drugs hydrochlorothiazide, amlodipine besylate, valsartan and pharmaceutical excipients. The three components all belong to hydrophobic drugs, so that the dissolution rate is one of the key indicators measuring the intrinsic quality of the preparation. A specific ratio of the raw materials to the excipients is adopted by the invention, especially a polyoxyethylene-polyoxypropylene copolymer is used, for instance poloxamer serves as a solubilizing agent, so that compared with the anti-hypertensive compound preparation EXFORGE HCT produced by American Novartis pharmaceutical company, the compound preparation has good similarity in terms of dissolution behavior. According to the invention, wet granulation or dry granulation is employed to effectively solve the problems of low bulk density, poor liquidity, strong moisture absorption, and sticking and picking of Valsartan. The preparation method of the compound preparation is simple and practical, and the product has stable quality, and good dissolution rate and content uniformity of each effective component, thus being suitable for large-scale industrial production.
The present invention relates to new species-selective phage endolysins and their use to treat bacterial vaginosis (BV). The present invention provides recombinant endolysins, i.e. domain-swapped endolysins. The invention also relates to said endolysins for use in treating diseases or disorders such as bacterial infections, in particular BV. The invention further relates to polynucleotides encoding said endolysins. Said polynucleotides can also be used for treating such diseases or disorders. Also provided by the present invention is a pharmaceutical composition comprising an endolysin of the invention for use in treating such diseases or disorders. Said endolysins, polynucleotides and pharmaceutical composition may be administered locally, in particular locally into the vagina.
AIMS: To estimate the contemporary trend in the prevalence of sarcopenia and evaluate its risk factors and the longitudinal associations with multiple chronic conditions and mortality among Chinese middle-aged and older adults.
METHODS: This was a nationwide, prospective cohort study using data from the China Health and Retirement Longitudinal Study. The definition of sarcopenia was based on the Asian Working Group for Sarcopenia 2019 algorithm. In the cross-sectional analysis, we estimated the trend in the weighted prevalence of sarcopenia from 2011 to 2015 and examined the associated risk factors for sarcopenia severity in 2011. In the longitudinal analysis, we assessed the longitudinal associations between sarcopenia and 14 chronic conditions and mortality during a 9-year follow-up.
RESULTS: The weighted prevalence of sarcopenia remained consistently high in the overall population from 2011 (15.9%, 95% confidence intervals [CI]: 15.1, 16.6) to 2015 (15.0%, 95% CI: 14.3, 15.6; p for trend = 0.075). A range of risk factors were independently associated with the severity of sarcopenia, including older age, female sex, lower socioeconomic status, smoking status, malnutrition, and several chronic conditions. Possible sarcopenic and sarcopenic individuals had higher odds of several chronic conditions (i.e., heart disease, chronic lung disease, and memory-related disease) and increased risks of mortality (possible sarcopenia: odds ratios (OR): 1.66, 95% CI: 1.37, 2.00; sarcopenia: OR: 1.69, 95% CI: 1.36, 2.11) in 9 years of follow-up.
CONCLUSIONS: The prevalence of sarcopenia remained consistently high in the investigated population. Various risk factors were significantly associated with a higher prevalence of sarcopenia. Sarcopenic individuals had higher odds of several chronic conditions and increased risks of mortality, highlighting that the urgent need for dedicated efforts to improve the management of sarcopenic patients.
The invention provides an electuary for treating senile constipation. Senile constipation is different from common habitual constipation; most elder people have basic problems of yin deficiency, blood dryness, deficiency and non-flowing of qi and the like and are hardly vulnerable to dryness heat, qi stagnation, etc. at the same time, so long-term taking of a single aperitive usually produces a weak effect, and catharsis easily causes problems like increasingly deficient healthy qi; thus, to fill a gap in the prior art, the electuary for treating senile constipation is invented by using differentiation theory of the traditional Chinese medicine. The electuary comprises the following traditional Chinese medicines: 15% of milkvetch root, 10% of honeysuckle flower, 8% of clematis root, 10% of white peony root, 10% of hemp seed, 10% of desert cistanche, 7% of magnolia obavata, 10% of Chinese angelica, 3% of rhizoma corydalis, 5% of banksia rose, 6% of eucommia bark and 6% of rhubarb stir-fried with wine. The above-mentioned twelve traditional Chinese medicines are uniformly mixed and then undergo ultrafine grinding so as to prepare the electuary. Elder patients should swallow 10 to 20 g of the electuary with warm boiled water on an empty stomach each time, three times each day and do appropriate exercise, drink more water and eat more fruit and vegetable at the same time.
A method includes receiving a first set of identifiers selected based on commonality among descriptive data corresponding to the identifiers of the first set. Each identifier corresponds to a user who has been supplied a physical object. The method includes identifying event data for the first set within a specified epoch. The method includes training a machine learning model for the first set using the identified event data. The machine learning model is trained using parallel processing of records from a storage structure storing the event data. The parallel processing includes assigning analysis of the event data of each of a subset of the first set to respective processor threads for parallel execution on processing hardware. The trained machine learning model is configured to receive a selected identifier and generate an output representing an amount of resources expected to be used by the selected identifier for a subsequent epoch.
SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the experimental group.